Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared. This study retrospectively evaluated 373 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Won‐Mook, Choi, Jonggi, Lee, Danbi, Shim, Ju Hyun, Lim, Young‐Suk, Lee, Han Chu, Chung, Young‐Hwa, Lee, Young‐Sang, Park, Sook Ryun, Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Lee, So Jung, Kim, Kang Mo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327222/
https://www.ncbi.nlm.nih.gov/pubmed/32626838
http://dx.doi.org/10.1002/hep4.1523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327222/
https://www.ncbi.nlm.nih.gov/pubmed/32626838
http://dx.doi.org/10.1002/hep4.1523

Ejemplares similares